Evidence map›Paper›PMID 35386001›Full record

ArticleJournal of cancer research and clinical oncology2022

Blimp-1 is a prognostic indicator for progression of cervical intraepithelial neoplasia grade 2.

Mayumi Saito, Aarthi Rajesh, Carrie Innes, Rachael van der Griend, Peter Fitzgerald, Bryony Simcock, Peter Sykes, Merilyn Hibma

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mayumi SaitoDepartment of Pathology, Dunedin School of Medicine, University of Otago, P O Box 56, Dunedin, New Zealand.
Aarthi RajeshDepartment of Pathology, Dunedin School of Medicine, University of Otago, P O Box 56, Dunedin, New Zealand.
Carrie InnesDepartment of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand.
Rachael van der GriendCanterbury Health Laboratories, Christchurch, New Zealand.
Peter FitzgeraldSouthern Community Laboratories, Dunedin, New Zealand.
Bryony SimcockDepartment of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand.
Peter SykesDepartment of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand.
Merilyn HibmaDepartment of Pathology, Dunedin School of Medicine, University of Otago, P O Box 56, Dunedin, New Zealand. merilyn.hibma@otago.ac.nz.ORCID http://orcid.org/0000-0002-7918-613X
University of Otago · NZCanterbury Health Laboratories · NZSouthern Community Laboratories (New Zealand) · NZ

Funding

Genesis Oncology Trust 2016
6 · The paper itself

Abstract

backgroundProgression of cervical intraepithelial neoplasia (CIN) to higher grade disease is associated with persistent human papillomavirus (HPV) infection and an absence of immune-mediated regression. However, the immune microenvironment that distinguishes progression from persistent or regressing lesions has not been well defined.

methodsA total of 69 patients under the age of 25 with high-risk HPV-positive cytology and biopsy-confirmed p16-positive CIN2 were included in the study. Biopsies were stained using 20 antibodies to a range of immune markers. Based on a 2-year follow-up, samples were analysed in "progressor" (CIN3 +) or "persister/regressor" (CIN1, 2 or normal) groups.

resultsProgression was most strongly associated with Blimp-1 positive cell staining in the lesion (P = 0.0019) and with low numbers of infiltrating CD4 cells in the dermal region beneath the lesion (P = 0.0022). The presence of CD4, CD8 and T bet-positive cells in the dermal region most strongly correlated with CD11c cells in the persister/regressor but not the progressor group.

conclusionHigh numbers of Blimp-1 + cells in CIN2 lesions may predict progression to more severe disease. Measurement of Blimp-1 may have diagnostic utility for the determination of the need to treat women with cervical pre-cancer. HIGHLIGHTS: CIN2 progression is associated with high numbers of Blimp-1 positive cells in the lesion. Detection of Blimp-1 in the lesion may have utility as a prognostic test to inform the need to treat CIN2.

Indexed as

Papillomavirus InfectionsPositive Regulatory Domain I-Binding Factor 1Uterine Cervical DysplasiaUterine Cervical NeoplasmsBiopsyCyclin-Dependent Kinase Inhibitor p16FemaleHumansPapillomaviridaePrognosisTumor MicroenvironmentCyclin-Dependent Kinase Inhibitor p16Positive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanBiomarkersCervical intraepithelial neoplasiaHigh-grade squamous intraepithelial lesionHuman papillomavirusPrognosis

Identifiers

PMID35386001
PMCPMC9294030
OpenAlexW4225642224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.